Browse by Clinical Topic:

Featured CME/CE Content:
neuroscienceCME Editors' Picks:

IrAEs in Emergency Medicine: Have You Missed It?

Premiere Date: Friday, December 30, 2022

This activity will offer CE credit for:

  1. Pharmacy (acpe)

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Creditâ„¢

Credit Expiration Date:
Saturday, December 30, 2023
Note: Credit Is No Longer Available


Jimmy L. Pruitt III, PharmD, BCPS, BCCCPJimmy L. Pruitt III, PharmD, BCPS, BCCCP 
Emergency Medicine Clinical Pharmacy Specialist
Medical University of South Carolina Health
Charleston, SC

Monica Wattana, MD, FAAEMMonica Wattana, MD, FAAEM 
Associate Professor of Emergency Medicine
Director of Education
University of Texas MD Anderson Cancer Center
Houston, TX

Statement of Need

Immuno-oncology agents, such as immune checkpoint inhibitors (ICIs), are being increasingly used for the treatment of cancer. Treatment with ICIs can result in immune-related adverse events (irAEs) which require prompt recognition and treatment. However, emergency department (ED) management of irAEs is suboptimal due to lack of clinician familiarity with irAE presentation and onset and the overlap of irAE presentation with other common medical complaints. ED pharmacists play an important role in the management of drug-related adverse events, however, education is needed to improve pharmacist ability to identify patients with a history of ICI treatment, and to recognize and manage irAEs.

In this CMEO BriefCase, Drs. Pruitt and Wattana will guide learners through a patient case scenario reviewing the recognition of ICI exposure through focused medication history, signs and symptoms of irAEs, and principles of early, appropriate management and the importance of consultation with an oncology care team. This program will focus on the role of the ED pharmacist in making timely interventions for patients with irAEs seen in the emergency department including strategies for engaging with ED team members and for setting the patient up for a successful transition in care.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Recommend escalating treatment interventions and consultation to appropriate specialists for complex irAE scenarios.

Financial Support

Supported by an educational grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Target Audience

Pharmacists in outpatient, ambulatory, or community care settings.

Credit Information

Specific CE Credit information is not available at this time. Please check again soon!

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Pruitt reports no financial relationships to disclose.

Dr. Wattana reports no financial relationships to disclose.

The following peer reviewer and CME Outfitters staff have no financial relationships:

  • Joshua Caballero PharmD, BCPP, FCCP (peer reviewer)
  • Thomas Mitchell (planning committee)
  • Kasey Brandt, PharmD (planning committee)
  • Julie Strickland, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


    Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download